Edelman Steve V, Agardh Daniel, Cui Nancy, Hao Lichen, Wieloch Mattias, Meneghini Luigi
University of California San Diego, La Jolla, California, USA.
Taking Control of Your Diabetes 501(c)(3), San Diego, California, USA.
Diabetes Obes Metab. 2025 Aug;27(8):4229-4238. doi: 10.1111/dom.16454. Epub 2025 May 28.
The objective of this study was to compare the risk of developing type 1 diabetes in individuals with celiac disease, hyperthyroidism and hypothyroidism to that of individuals without those conditions.
In this retrospective, observational, matched-cohort study based on real-world claims data, individuals with at least one diagnosis of celiac disease, hyperthyroidism (e.g. Graves' disease) or hypothyroidism (e.g. Hashimoto's disease) and a control cohort of individuals without any of these three conditions were included. Individuals from the disease and control cohorts were propensity score matched 1:1 based on baseline demographics and clinical characteristics. A Cox proportional hazards model was used to compare the risk of type 1 diabetes between cohorts.
Type 1 diabetes developed in 0.14% (68/47 099) of individuals with celiac disease compared to 0.06% (27/47 099) of controls. Of those with hyperthyroidism, type 1 diabetes developed in 0.17% (281/164 830) compared to 0.06% (99/164 830) of controls. Of those with hypothyroidism, type 1 diabetes developed in 0.18% (1756/980 477) compared to 0.08% (764/980 477) of controls. The risk of developing type 1 diabetes was increased for each of the disease cohorts compared to their respective controls (celiac disease: HR = 2.54 [p < 0.0001]; hyperthyroidism: adjusted HR = 2.98 [p < 0.0001]; hypothyroidism: HR = 2.41 [p < 0.0001]); risk was highest among individuals aged <18 years.
The risk of developing type 1 diabetes was significantly higher for individuals with celiac disease or thyroid disease compared to those without any of these conditions. These findings support the screening of individuals with these conditions for stage 2 type 1 diabetes.
本研究的目的是比较患有乳糜泻、甲状腺功能亢进和甲状腺功能减退的个体与未患这些疾病的个体患1型糖尿病的风险。
在这项基于真实世界索赔数据的回顾性、观察性、匹配队列研究中,纳入了至少有一次乳糜泻、甲状腺功能亢进(如格雷夫斯病)或甲状腺功能减退(如桥本氏病)诊断的个体,以及没有这三种疾病的个体组成的对照队列。根据基线人口统计学和临床特征,对疾病队列和对照队列中的个体进行倾向得分1:1匹配。使用Cox比例风险模型比较队列之间患1型糖尿病的风险。
乳糜泻患者中1型糖尿病的发病率为0.14%(68/47099),而对照组为0.06%(27/47099)。甲状腺功能亢进患者中,1型糖尿病的发病率为0.17%(281/164830),而对照组为0.06%(99/164830)。甲状腺功能减退患者中,1型糖尿病的发病率为0.18%(1756/980477),而对照组为0.08%(764/980477)。与各自的对照组相比,每个疾病队列患1型糖尿病的风险均增加(乳糜泻:HR = 2.54 [p < 0.0001];甲状腺功能亢进:调整后HR = 2.98 [p < 0.0001];甲状腺功能减退:HR = 2.41 [p < 0.0001]);风险在18岁以下个体中最高。
与没有这些疾病的个体相比,患有乳糜泻或甲状腺疾病的个体患1型糖尿病的风险显著更高。这些发现支持对患有这些疾病的个体进行2型1型糖尿病筛查。